subject: The Status Of Paclitaxel In Adjuvant Treatment Of Operable Breast Cancer [print this page] As a pioneer and representative of the taxane, paclitaxels status and role in the early adjuvant chemotherapy of breast cancer is consolidated. But in rapid clinical and basic research of breast cancer, especially in the individualized treatment of breast cancer trends increasingly clear environment, it is also facing a great challenge, and can mainly be grouped into the following aspects: professional physicians and patients need to be clear once again the benefits that adding paclitaxel to adjuvant chemotherapy. Whether the taxol time and dose have impact on its efficacy, or whether the weekly program is more advantageous than three weeks program. Whether Breast cancer molecular biological indicators such as hormone receptor, Her-2 status affect the benefit of paclitaxel in the adjuvant chemotherapy. The outcome of paclitaxel and other molecular targeted drugs efficacy and toxicity (especially cardiac toxicity).
Paclitaxel (Taxol)s position in the surgical adjuvant treatment of breast cancer has been long-term forward-looking Clinical Research Institute confirmed. Confirmed taxane (Paclitaxel or docetaxel) to join the ring class program of adjuvant chemotherapy for breast cancer compared with conventional anthracene anthracycline program can be further improved since the 1990s a number of key randomized Phase clinical trials patients with disease-free survival and overall survival.
Although meta-analysis also confirmed that paclitaxel in anthracycline basis to further improve disease-free survival and overall survival, but as an adjuvant therapy principle, always looking for the maximum chance of cure. Paclitaxel weekly program based on the following theory: the anti-tumor and anti-neovascularization can be reflected in lower concentrations, so the rhythm of land administration can maximize the role of anti-neovascularization, but also the feasibility of paclitaxel weekly therapy been confirmed.
The significance of various molecular markers of breast cancer in the breast cancer natural history and treatment decision-making increasingly respected individual in the treatment of breast cancer, how to determine adjuvant therapy based on molecular characterization of a specific tumor. The choice of resveratrol programs is an important issue. Perhaps one day, the detection of gene chips really can be done on the efficacy of foresight, but today, at least several important prognostic and predictive indicators can give us some tips on the sensitivity of adjuvant treatment of taxol.
Molecular targeted drugs application field in breast cancer has transferred from advanced and metastatic disease to the application in adjuvant treatment of operable breast cancer. The drugs and cytotoxic drugs is inevitable in application of sequential or combination modes. In this process, the long-term efficacy of conclusive evidence and whether the toxicity overlay that affect the survival benefit of patients is another focus. As an important drug in adjuvant therapy for operable breast cancer and metastatic breast cancer treatment, there are still many cutting-edge issues need further study in the clinical use of paclitaxel (taxol).Source:http://www.cospcn.com
by: anelwew
welcome to Insurances.net (https://www.insurances.net)
